- Stocks
- Pharma & Healthcare
- Smruthi Organic
Smruthi Organic share price
NSE: SMRUTHIORGPharma & HealthcareDrug Manufacturers - Specialty & Generic
Smruthi Organic at a glance
With a market capitalisation of ₹135 Cr, it ranks 2495th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 5.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹29 Cr (−23.6% year on year) and net profit ₹1 Cr (−52.0%), on a standalone basis. Promoters held 64.73% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹135 CrRank 2495 on NSE
- Price to book
- 1.76×FY25
- EPS (TTM)
- ₹2.99to Q4 FY26
- ROE
- 5.0%FY25
- ROCE
- 8.4%FY25
- Debt to equity
- 0.23FY25
- Net profit margin
- 2.8%FY25
- Book value / share
- ₹62.58FY25
- Dividend payout
- 48.2%FY25
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Smruthi Organic quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹27 Cr | ₹29 Cr | ₹31 Cr | ₹38 Cr | ₹19 Cr | ₹32 Cr | ₹22 Cr | ₹29 Cr |
| Revenue YoY | −21.9% | −0.7% | +33.1% | −4.0% | −30.4% | +7.5% | −28.7% | −23.6% |
| Net profit | −₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | −₹1 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr |
| Net profit YoY | −140.2% | −62.3% | — | +46.7% | — | +164.1% | −5.4% | −52.0% |
| Net margin | −3.4% | 2.7% | 4.7% | 5.9% | −5.8% | 6.5% | 6.3% | 3.7% |
| EPS | −₹0.81 | ₹0.68 | ₹1.29 | ₹1.95 | −₹0.96 | ₹1.80 | ₹1.22 | ₹0.93 |
Smruthi Organic financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹131 Cr | ₹127 Cr | ₹133 Cr | ₹141 Cr | ₹128 Cr | ₹126 Cr |
| Operating profit | ₹12 Cr | ₹24 Cr | ₹14 Cr | ₹4 Cr | ₹5 Cr | ₹5 Cr |
| Net profit | ₹8 Cr | ₹17 Cr | ₹10 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| EPS (₹) | ₹22.14 | ₹14.95 | ₹9.07 | ₹3.87 | ₹3.14 | ₹3.11 |
| Cash from operations | ₹21 Cr | ₹23 Cr | ₹2 Cr | ₹12 Cr | ₹4 Cr | ₹10 Cr |
| Total debt | ₹2 Cr | ₹2 Cr | ₹0 Cr | ₹1 Cr | ₹6 Cr | ₹8 Cr |
| Shareholders' equity | ₹42 Cr | ₹60 Cr | ₹67 Cr | ₹68 Cr | ₹70 Cr | ₹72 Cr |
Smruthi Organic shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 64.73% | 64.73% | 64.73% | 64.73% | 64.73% | 64.73% |
| Non-institutions | 35.27% | 35.27% | 35.27% | 35.27% | 35.27% | 35.27% |
Smruthi Organic vs peers
The listed Pharma & Healthcare companies nearest to Smruthi Organic by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SMRUTHIORGSmruthi Organic | — | — | — | ₹135 Cr | — | — |
| LACTOSELactose India | — | — | — | ₹132 Cr | — | — |
| VALENCIAValencia Nutrit | — | — | — | ₹132 Cr | — | — |
| PARPar Drugs And Chemicals | ₹105.25 | −2.64% | +1.7% | ₹130 Cr | 9.9 | — |
| ASPIRAAspira Pathlab | — | — | — | ₹125 Cr | — | — |
| PARNAXLABParnax Lab | ₹108.95 | −3.52% | — | ₹125 Cr | 10.6 | — |
| KREBSBIOKrebs Biochemicals and Industries | ₹57.16 | −5.99% | −20.6% | ₹123 Cr | — | — |
Ask anything about Smruthi Organic
Pivot answers on the live chart with evidence you can check, and tests strategies against SMRUTHIORG's own history. Try: “Why has SMRUTHIORG moved over the last three months?” · “Backtest a 50-day moving-average crossover on SMRUTHIORG over five years” · “Compare SMRUTHIORG with LACTOSE on margins and valuation”
Frequently asked questions about Smruthi Organic
What is the market cap of Smruthi Organic?
Smruthi Organic's market capitalisation is ₹135 Cr (₹135 Cr) at the 19 Oct 2026 close, ranking 2495th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Smruthi Organic?
Return on equity was 5.0% in FY25 and return on capital employed was 8.4% in FY25 (standalone figures).
Is Smruthi Organic a debt-free company?
No. Smruthi Organic's debt-to-equity ratio was 0.23 in FY25, with total debt of ₹8 Cr.
What were Smruthi Organic's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Smruthi Organic reported revenue of ₹29 Cr, −23.6% year on year, and net profit of ₹1 Cr, −52.0% year on year.
What is the shareholding pattern of Smruthi Organic?
As of 30 Jun 2026: promoters 64.73%, non-institutions 35.27%.
Who are Smruthi Organic's competitors?
The listed Pharma & Healthcare companies closest to Smruthi Organic by market cap are Lactose India, Valencia Nutrit, Par Drugs And Chemicals, Aspira Pathlab, Parnax Lab and Krebs Biochemicals and Industries.
Is Smruthi Organic a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Smruthi Organic's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SMRUTHIORG against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text